1. A method for treating rheumatoid arthritis in a patient with clinical efficacy estimated by lowering DAS28-CRP (28 joint disease activity index including measuring C-reactive protein) by more than 1.2 and / or by at least 20% improvement treatment efficacy (ACR 20) as defined by the 1987 American College of Rheumatology (ACR) criteria, the method comprising administering to a patient a composition comprising a therapeutically effective amount of a GM-CSFRα inhibitor, wherein the inhibitor binds to the Tyr-Leu-Asp-Phe-GIn motif in polo in sequences 226-230 of the sequence SEQ ID NO: 206 of human GM-CSFRα and inhibits the binding of GM-CSF to GM-CSFRα, and where the inhibitor binds to the extracellular domain of human GM-CSFRα with affinity (KD) of 5 nM or less in a surface plasma resonance analysis .2. A method according to claim 1, characterized in that the clinical efficacy includes remission of rheumatoid arthritis or a reduced time before the onset of remission of rheumatoid arthritis. A method according to claim 2, characterized in that the clinical efficacy includes remission of rheumatoid arthritis in at least 10% or at least 20% of patients. The method of claim 2, wherein the clinical efficacy comprises an improvement of at least 20% of the treatment efficacy (ACR 20) as determined by the 1987 ACR criteria； or where clinical efficacy includes at least a 50% improvement in treatment efficacy (ACR 50) as determined by the 1987 ACR criteria； or where clinical efficacy includes at least 70% improvement in treatment efficacy (ACR 70) as determined by the 1987 ACR criteria. 5. The method according to claim 4, characterized in that the clinical efficacy1. Способ лечения ревматоидного артрита у пациента с обеспечением клинической эффективности, оцениваемой по снижению DAS28-CRP (индекса активности заболевания по 28 суставам, включающего измерение С-реактивного белка) более чем на 1,2 и/или улучшению по меньшей мере на 20% эффективности лечения (ACR 20), как опреде
